Send us a message
If you would like more information on Focalis Bio and our development of cutting-edge gene therapies targeting focal refractory epilepsy (FRE) please fill out the form below:
News
-
Focalis Bio appoints Dr Teresa Nunes as Chief Medical Officer
Appointment of senior clinical leader will support progression of lead candidate EPY201 through the clinic.
-
Focalis Bio partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy
ClearPoint Neuro’s system enables precise delivery to the seizure focus, ensuring best possible efficacy and safety of Focalis Bio's investigational gene therapy. Partnership will support first-in-human Phase 1/2a clinical trials of EPY201 in patients with focal refractory epilepsy.
-
Focalis Bio announces completion of the large animal biodistribution studies supporting lead program EPY201
Focalis Bio, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy.
-
Focalis Bio appoints Professor Dimitri Kullmann as Chief Scientific Officer
Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy.
-
Focalis Bio raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE).
-
Focalis Bio announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201
Focalis Bio, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy...
